Literature DB >> 23959472

Prognostic role of cytovillin expression in patients with osteosarcoma: a meta-analysis.

Shibing Guo, Rui Bai, Wei Zhao, Yuxin Wang, Zhenqun Zhao, Wei Feng.   

Abstract

Cytovillin plays structural and regulatory roles in the assembly and stabilization of specialized plasma membrane domains and in the tumor angiogenesis. Cytovillin expression has been proposed to be an effective biomarker of prognosis in patients with osteosarcoma, and many studies have been performed to assess the prognostic role of cytovillin expression in patients with osteosarcoma. We performed this meta-analysis to provide a comprehensive evaluation of the role of cytovillin expression on the overall survival rate by calculating the pooled risk ratio (RR) with corresponding 95% confidence interval (95% CI). Finally, eight studies with a total of 415 patients with osteosarcoma were included into the meta-analysis. Meta-analysis of total eight studies showed that cytovillin expression was obviously associated with lower overall survival rate in patients with osteosarcoma (RR = 0.41, 95% CI 0.28–0.58, P < 0.001). Meta-analysis of five studies with large sample still showed that cytovillin expression was obviously associated with lower overall survival rate (RR = 0.48, 95% CI 0.38–0.60, P < 0.001). In conclusion, the meta-analysis shows that cytovillin expression is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23959472     DOI: 10.1007/s13277-013-1065-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors.

Authors:  Isidro Machado; Samuel Navarro; Francisco Giner; Marco Alberghini; Franco Bertoni; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2010-06-16       Impact factor: 4.064

3.  Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.

Authors:  Jonathan B McHugh; Dafydd G Thomas; Joseph M Herman; Michael E Ray; Laurence H Baker; N Volkan Adsay; Raja Rabah; David R Lucas
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

4.  Immunofluorescent and immunochemical evidence for the expression of cytovillin in the microvilli of a wide range of cultured human cells.

Authors:  R Pakkanen
Journal:  J Cell Biochem       Date:  1988-09       Impact factor: 4.429

Review 5.  A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.

Authors:  K Z Masrouha; R Khattab; A Tawil; A Abdallah; S Saghieh; R Haidar; M Abboud; N J Khoury
Journal:  J Bone Joint Surg Br       Date:  2012-03

Review 6.  Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors.

Authors:  Sławomir Poletajew; Lukasz Fus; Aleksander Wasiutyński
Journal:  Ortop Traumatol Rehabil       Date:  2011 Nov-Dec

7.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 8.  Osteosarcoma.

Authors:  J Ritter; S S Bielack
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

Review 9.  The Janus-faced role of ezrin in "linking" cells to either normal or metastatic phenotype.

Authors:  Daria Brambilla; Stefano Fais
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

Review 10.  Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures.

Authors:  A Bretscher; D Reczek; M Berryman
Journal:  J Cell Sci       Date:  1997-12       Impact factor: 5.285

View more
  1 in total

1.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.